Skip to content

Humana HUM Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

CVS Health logo
CVS HealthCVS
UnitedHealth Group logo
UnitedHealth GroupUNH
HCA Healthcare logo
HCA HealthcareHCA
Centene logo
CenteneCNC
Molina Healthcare logo
Molina HealthcareMOH
Cigna logo
CignaCI

Other financials

Income statement

See full
Revenue$39.6B+23.5%
Operating income$1.8B-12.9%
Net income$1.2B-4.7%
EPS (diluted)$9.83-4.6%

Balance sheet

See full
Cash & equivalents$5.0B+16.5%
Total debt$14.0B+5.2%
Total equity$18.6B+4.7%
Total assets$55.3B+8.5%

Cash flow

See full
Operating cash flow$1.3B+279%
CapEx$121.0M+27.4%
Free cash flow$1.1B+380%

Valuation

See full
Market cap$46.74B+67.3%
Enterprise value$55.78B+52.9%
P/E14.8×-1.8×
P/S0.3×+0.1×

Profitability

See full
Operating margin2.7%-1.7pp
Net margin3%-0.1pp
FCF margin4.2%

Returns & leverage

See full
Return on equity18.2%+0.9pp
Debt / equity0.8×0.0×
Current ratio1.8×-0.1×

Where this comes from

Reported directly by Humana in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Humana’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Humana's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Humana's deferred tax assets and other non-current assets?
Humana (HUM) reported deferred tax assets and other non-current assets of $3.28B in Q1 2026.
How has Humana's deferred tax assets and other non-current assets changed year-over-year?
Humana's deferred tax assets and other non-current assets decreased by 2.9% year-over-year, from $3.38B to $3.28B.
What is the long-term trend for Humana's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Humana's deferred tax assets and other non-current assets has grown at a 8.0% compound annual growth rate (CAGR), from $2.13B to $3.13B.